Jack Lin, Ph.D.

Senior Director, New Technologies at Harpoon Therapeutics

Jack is currently a Sr. Director at Harpoon Therapeutics, where he and his team are focused on developing new T cell engager prodrugs and advancing Harpoon’s lead protease-activated T cell engager program, HPN601, from idea to IND. Before joining Harpoon, Jack was at CytomX developing protease-activated antibody drug conjugates and was an antibody engineer at Pfizer. He obtained his BS from the University of Toronto, PhD from Northwestern University, and was a postdoctoral research fellow at Genentech.